Prostate Cancer
Research


Volume 8 Number 9
September 2020


Home > Disciplines > Publications > Prostate Cancer Research > Volume 8, Year 2020 > Number 9, September



Contents


Case reports


Diagnosis, presentation


Epidemiology, risk factors, prevention


Follow-up, side effects, quality of life


Integrative medicine


Overall management


Prognosis, outcomes


Treatment



Case reports


Chaurasia AR, Smith CP, Pinto P, Wood B, Schott E, Cooley-Zgela T, Madan R, Lindenberg L, Mena E, Choyke P, Citrin D, Turkbey B.
Local failure after definitive radiation treatment of lymph-node positive prostate cancer: supporting the use of novel imaging techniques to personalize treatment options.
BJR Case Rep. 2020 Apr 17. 2020;6(3):20200001. doi: 10.1259/bjrcr.20200001. Case report. _



Diagnosis, presentation


Ali Mohammadpour R, Alizadeh A, Barzegar MR, Akbarzadeh Pasha A.
Association between prostate-specific antigen change over time and prostate cancer recurrence risk: A joint model.
Caspian J Intern Med. 2020 May 21. 2020;11(3):324-328. doi: 10.22088/cjim.11.3.324. Retrospective study. _




Anastay V, Gondran-Tellier B, McManus R, Delonca R, Akiki A, Gaillet S, Delaporte V, Andre M, Daniel L, Karsenty G, Lechevallier E, Boissier R, Baboudjian M.
Nonsuspicious prebiopsy multiparametric MRI: is prostate biopsy still necessary?
Abdom Radiol (NY). 2020 Sep 9. doi: 10.1007/s00261-020-02728-8. Retrospective study. _




Borrelli P, Larsson M, Ulén J, Enqvist O, Trägårdh E, Hvid Poulsen M, Mortensen MA, Kjölhede H, Høilund-Carlsen PF, Edenbrandt L.
Artificial Intelligence-based detection of lymph node metastases by PET/CT predicts prostate cancer-specific survival.
Clin Physiol Funct Imaging. 2020 Sep 25. doi: 10.1111/cpf.12666. Clinical tool development. _




Brunese L, Mercaldo F, Reginelli A, Santone A.
Radiomics for Gleason Score Detection through Deep Learning.
Sensors (Basel). 2020 Sep 21. 2020;20(18):E5411. doi: 10.3390/s20185411. Clinical tool development. _




Caglar M, Tuncel M, Yildiz E, Karabulut E.
Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Ann Nucl Med. 2020 Sep 25. doi: 10.1007/s12149-020-01529-9. Retrospective study. _




Chandramouli S, Leo P, Lee G, Elliott R, Davis C, Zhu G, Fu P, Epstein JI, Veltri R, Madabhushi A.
Computer Extracted Features from Initial H&E Tissue Biopsies Predict Disease Progression for Prostate Cancer Patients on Active Surveillance.
Cancers (Basel). 2020 Sep 21. 2020;12(9):E2708. doi: 10.3390/cancers12092708. Clinical tool development. _




Dong L, Zhu Y, Xin M, Dong B, Pan J, Liu J, Amend SR, Xue W, Pienta KJ, Rowe SP.
Prospective evaluation of 68Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level.
Med Oncol. 2020 Sep 12. 2020;37(10):89. doi: 10.1007/s12032-020-01412-7. Prospective study. _




Falagario UG, Lantz A, Jambor I, Martini A, Ratnani P, Wagaskar V, Treacy PJ, Veccia A, Bravi CA, Bashorun HO, Phillip D, Lewis S, Haines K, Cormio L, Carrieri G, Tewari A.
Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.
Int J Urol. 2020 Sep 27. doi: 10.1111/iju.14385. Retrospective study. _




Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Fossati N, Martini A, Cucchiara V, Picker W, Haug E, Ratnani P, Haines K, Lewis S, Sujit N, Selvaggio O, Sanguedolce F, Macarini L, Cormio L, Nordström T, Tewari A, Briganti A, Boström PJ, Carrieri G.
Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
Eur Urol Oncol. 2020 Sep 21. 2020;S2588-9311(20)30142-5. doi: 10.1016/j.euo.2020.08.014. Retrospective study. _




Flammia S, Frisenda M, Maggi M, Magliocca FM, Ciardi A, Panebianco V, De Berardinis E, Salciccia S, Di Pierro GB, Gentilucci A, Del Giudice F, Busetto GM, Gallucci M, Sciarra A.
Cribriform pattern does not have a significant impact in Gleason Score ≥7/ISUP Grade ≥2 prostate cancers submitted to radical prostatectomy.
Medicine (Baltimore). 2020 Sep 18. 2020;99(38):e22156. doi: 10.1097/MD.0000000000022156. Prospective study. _




Herlemann A, Overland MR, Washington SL 3rd, Cowan JE, Westphalen AC, Carroll PR, Nguyen HG, Shinohara K, Cooperberg MR.
How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?
Eur Urol Focus. 2020 Aug 28. 2020;S2405-4569(20)30216-9. doi: 10.1016/j.euf.2020.08.003. Prospective study. _




Hosseiny M, Felker ER, Azadikhah A, Suvannarerg V, Sayre J, Ponzini D, Ahuja P, Lu D, Raman SS.
Efficacy of 3T Multiparametric MR Imaging followed by 3T in-Bore MR-Guided Biopsy for Detection of Clinically Significant Prostate Cancer Based on PIRADSv2.1 Score.
J Vasc Interv Radiol. 2020 Sep 10. 2020;31(10):1619-1626. doi: 10.1016/j.jvir.2020.03.002. Retrospective study. _




Kang H, Kim EE, Shokouhi S, Tokita K, Shin HW.
Texture Analysis of F-18 Fluciclovine PET/CT to Predict Biochemically Recurrent Prostate Cancer: Initial Results.
Tomography. 2020 Sep;6(3):301-307. doi: 10.18383/j.tom.2020.00029. Retrospective study. _




Kim CH, Kim CK, Park JJ, Park SY, Yoon YC.
Yield of concurrent systemic biopsy during MRI-targeted biopsy according to Prostate Imaging Reporting and Data System version 2 in patients with suspected prostate cancer.
Eur Radiol. 2020 Sep 10. doi: 10.1007/s00330-020-07167-z. Retrospective study. _




Kim H, Kim JK, Hong SK, Jeong CW, Ku JH, Kwak C.
Role of multiparametric magnetic resonance imaging to predict postoperative Gleason score upgrading in prostate cancer with Gleason score 3 + 4.
World J Urol. 2020 Aug 31. doi: 10.1007/s00345-020-03421-7. Retrospective study. _




Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J.
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Eur Urol Oncol. 2020 Sep 18. 2020;S2588-9311(20)30139-5. doi: 10.1016/j.euo.2020.08.012. Retrospective study. _




Liu H, Tang K, Xia D, Wang X, Zhu W, Wang L, Yang W, Peng E, Chen Z.
Added Value of Biparametric MRI and TRUS-Guided Systematic Biopsies to Clinical Parameters in Predicting Adverse Pathology in Prostate Cancer.
Cancer Manag Res. 2020 Aug 24. 2020;12:7761-7770. doi: 10.2147/CMAR.S260986. Clinical tool development. _




Luzzago S, de Cobelli O, Mistretta FA, Piccinelli ML, Lorusso V, Morelli M, Bianchi R, Catellani M, Cozzi G, Di Trapani E, Pricolo P, Alessi S, Ferro M, Marvaso G, Matei DV, Jereczek-Fossa BA, Petralia G, Musi G.
MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
Prostate Cancer Prostatic Dis. 2020 Sep 28. doi: 10.1038/s41391-020-00290-4. Retrospective study. _




Porreca A, Del Giudice F, Giampaoli M, D'Agostino D, Romagnoli D, Corsi P, Del Rosso A, Maggi M, Chung BI, Ferro M, de Cobelli O, Lucarelli G, Schiavina R, De Berardinis E, Sciarra A, Busetto GM.
Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study.
Medicine (Baltimore). 2020 Sep 11. 2020;99(37):e22059. doi: 10.1097/MD.0000000000022059. Randomized trial. _




Rehman A, El-Zaatari ZM, Han SH, Shen SS, Ayala AG, Miles B, Divatia MK, Ketcham MS, Chung BM, Rogers JT, Ro JY.
Seminal vesicle invasion combined with extraprostatic extension is associated with higher frequency of biochemical recurrence and lymph node metastasis than seminal vesicle invasion alone: Proposal for further pT3 prostate cancer subclassification.
Ann Diagn Pathol. 2020 Aug 24. 2020;49:151611. doi: 10.1016/j.anndiagpath.2020.151611. Retrospective study. _




Sokhi HK, Padhani AR, Patel S, Pope A.
Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice.
Clin Radiol. 2020 Sep 9. 2020:S0009-9260(20)30356-1. doi: 10.1016/j.crad.2020.08.011. Retrospective study. _




Wang L, Yu F, Yang L, Zang S, Xue H, Yin X, Guo H, Sun H, Wang F.
68Ga-PSMA-11 PET/CT combining ADC value of MRI in the diagnosis of naive prostate cancer: Perspective of radiologist.
Medicine (Baltimore). 2020 Sep 4. 2020;99(36):e20755. doi: 10.1097/MD.0000000000020755. Retrospective study. _




Waeckel T, Ait Said K, Altieri M, Belin A, Doerfler A, Tillou X.
Over-diagnosed prostate cancer in solid organ recipients: lessons from the last 3 decades.
Int Urol Nephrol. 2020 Sep 14. doi: 10.1007/s11255-020-02636-2. Retrospective study. _




Walker SM, Mehralivand S, Harmon SA, Sanford T, Merino MJ, Wood BJ, Shih JH, Pinto PA, Choyke PL, Turkbey B.
Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection.
AJR Am J Roentgenol. 2020 Sep 2. 2020;1-6. doi: 10.2214/AJR.19.22679. Prospective study. _




Westphalen AC, McCulloch CE, Anaokar JM, Arora S, Barashi NS, Barentsz JO, Bathala TK, Bittencourt LK, Booker MT, Braxton VG, Carroll PR, Casalino DD, Chang SD, Coakley FV, Dhatt R, Eberhardt SC, Foster BR, Froemming AT, Fütterer JJ, Ganeshan DM, Gertner MR, Mankowski Gettle L, Ghai S, Gupta RT, Hahn ME, Houshyar R, Kim C, Kim CK, Lall C, Margolis DJA, McRae SE, Oto A, Parsons RB, Patel NU, Pinto PA, Polascik TJ, Spilseth B, Starcevich JB, Tammisetti VS, Taneja SS, Turkbey B, Verma S, Ward JF, Warlick CA, Weinberger AR, Yu J, Zagoria RJ, Rosenkrantz AB.
Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel.
Radiology. 2020 Apr 21. 2020;296(1):76-84. doi: 10.1148/radiol.2020190646. Retrospective study. _



Epidemiology, risk factors, prevention


Boeri L, Capogrosso P, Cazzaniga W, Ventimiglia E, Pozzi E, Belladelli F, Schifano N, Candela L, Alfano M, Pederzoli F, Abbate C, Montanari E, Valsecchi L, Papaleo E, Viganò P, Rovere-Querini P, Montorsi F, Salonia A.
Infertile Men Have Higher Prostate-specific Antigen Values than Fertile Individuals of Comparable Age.
Eur Urol. 2020 Aug 17. 2020;S0302-2838(20)30615-1. doi: 10.1016/j.eururo.2020.08.001. Cross-sectional study. _




Gul M, Serefoglu EC.
Is Infertility a Predictor of Prostate Cancer?
Eur Urol. 2020 Sep 16. 2020;S0302-2838(20)30696-5. doi: 10.1016/j.eururo.2020.09.005. Comment. _
Referring to
Boeri L, et al.,
Infertile Men Have Higher Prostate-specific Antigen Values than Fertile Individuals of Comparable Age. Eur Urol. 2020 Aug 17. 2020;S0302-2838(20)30615-1. doi: 10.1016/j.eururo.2020.08.001. Cross-sectional study. _



Follow-up, side effects, quality of life

*

Bergius S, Roine RP, Taari K, Sintonen H.
Health-Related Quality of Life and Survival in Prostate Cancer Patients in a Real-World Setting.
Urol Int. 2020 Sep 21. 2020;1-9. doi: 10.1159/000510319. Survey & Retrospective study.
_




Boevé L, Hulshof MCCM, Verhagen PCMS, Twisk JWR, Witjes WPJ, de Vries P, van Moorselaar RJA, van Andel G, Vis AN.
Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
Eur Urol. 2020 Sep 22. 2020;S0302-2838(20)30640-0. doi: 10.1016/j.eururo.2020.08.023. Randomized controlled trial. _




Davey P, Kirby MG.
Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice.
World J Urol. 2020 Sep 26. doi: 10.1007/s00345-020-03433-3. Retrospective study. _




Fizazi K, Kramer G, Eymard JC, Sternberg CN, de Bono J, Castellano D, Tombal B, Wülfing C, Liontos M, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Oudard S, Facchini G, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, Bensfia S, de Wit R.
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Lancet Oncol. 2020 Sep 11. 2020;S1470-2045(20)30449-6. doi: 10.1016/S1470-2045(20)30449-6. Phase 4 trial. _




Ricco A, Mukhopadhyay N, Deng X, Holdford D, Skinner V, Saraiya S, Moghanaki D, Anscher MS, Chang MG.
Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial.
Front Oncol. 2020 Aug 21. 2020;10:1686. doi: 10.3389/fonc.2020.01686. Phase 1-2 trial. _ .




Royce TJ, Wang AZ, Chen RC.
Quality-of-life Benefits and Harms from Prostate Radiotherapy in Patients with Low-burden Metastatic Prostate Cancer.
Eur Urol. 2020 Sep 24. 2020;S0302-2838(20)30721-1. doi: 10.1016/j.eururo.2020.09.029. Comment. _
Referring to
Boevé L, et al.,Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial. Eur Urol. 2020 Sep 22. 2020;S0302-2838(20)30640-0. doi: 10.1016/j.eururo.2020.08.023. Randomized controlled trial. _




Shigeta K, Kikuchi E, Matsushima M, Ogihara K, Kosaka T, Mizuno R, Tanaka T, Shigematsu N, Oya M.
Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy.
Int J Urol. 2020 Sep 6. doi: 10.1111/iju.14358. Survey study. _



*

Slezak JM, Van Den Eeden SK, Cannavale KL, Chien GW, Jacobsen SJ, Chao CR.
Long-term follow-up of a racially and ethnically diverse population of men with localized prostate cancer who did not undergo initial active treatment.
Cancer Med. 2020 Sep 23. doi: 10.1002/cam4.3471. Retrospective study. _




Wu YH, Jhan JH, Ke HL, Tseng SI, Chang YH, Yeh HC, Li CC, Lee YC.
Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Int J Clin Pharm. 2020 Sep 20. doi: 10.1007/s11096-020-01143-9. Retrospective study. _




Xiao D, Guizard AV, Daubisse-Marliac L, Woronoff AS, Trétarre B, Delafosse P, Molinié F, Cowppli-Bony A, Lapôtre-Ledoux B, Bara S, Marrer E, Velten M, Laroche L, Heutte N, Grosclaude P, Joly F.
Evaluation of long-term living conditions in patients treated for localised prostate cancer.
Eur J Cancer Care (Engl). 2020 Sep 24. 2020;e13333. doi: 10.1111/ecc.13333. Retrospective study. _



Integrative medicine

*

Sawada N, Iwasaki M, Yamaji T, Shimazu T, Inoue M, Tsugane S.
Soy and isoflavone consumption and subsequent risk of prostate cancer mortality: the Japan Public Health Center-based Prospective Study.
Int J Epidemiol. 2020 Sep 23. 2020;dyaa177. doi: 10.1093/ije/dyaa177. Prospective study. _



Overall management


Raikhelkar J, Pham M, Lourenco L, Narang N, Chung B, Nguyen A, Kim G, Sayer G, Uriel N.
Heart transplantation in patients with localized prostate cancer-Are we denying a life-saving therapy due to an indolent tumor?
Clin Transplant. 2020 Sep 17. 2020;e14080. doi: 10.1111/ctr.14080. Survey study. _



Prognosis, outcomes


Ang M, Borg M, O'Callaghan ME; South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC).
Survival outcomes in men with a positive family history of prostate cancer: a registry based study.
BMC Cancer. 2020 Sep 18. 2020;20(1):894. doi: 10.1186/s12885-020-07174-9. Retrospective study. _




Goldberg H, Glicksman R, Woon D, Hoffman A, Shaikh H, Chandrasekar T, Klaassen Z, Wallis CJD, Ahmad AE, Sanmamed-Salgado N, Qu X, Moraes FY, Diamandis EP, Berlin A, Fleshner NE.
Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?
BJU Int. 2020 Sep 14. doi: 10.1111/bju.15236?. Retrospective study. _




Gomez-Iturriaga A, Büchser D, Miguel IS, Marban M, Urresola A, Ezquerro A, Gil A, Suarez F, Gonzalez A, Mairata E, Martinez-Indart L, Cacicedo J, Couñago F, Mínguez P, Casquero F.
MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?
Clin Transl Radiat Oncol. 2020 Aug 13. 2020;24:135-139. doi: 10.1016/j.ctro.2020.08.002. Prospective study. _




Guo XX, Liu SJ, Wang M, Hou HM, Wang X, Zhang ZP, Liu M, Wang JY.
Comparing the Oncological Outcomes of Cryoablation vs. Radical Prostatectomy in Low-Intermediate Risk Localized Prostate Cancer.
Front Oncol. 2020 Aug 26. 2020;10:1489. doi: 10.3389/fonc.2020.01489. Retrospective study. _




Ishikawa H, Higuchi K, Kaminuma T, Takezawa Y, Saito Y, Etsunaga T, Maruo K, Kawamura H, Kubo N, Nakano T, Kobayashi M.
The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of prostate cancer after prostatectomy.
J Radiat Res. 2020 Sep 5. 2020;rraa074. doi: 10.1093/jrr/rraa074. Retrospective study. _




Kim SH.
Development and External Validation of Multiparametric MRI-Derived Nomogram to Predict Risk of Pathologic Upgrade in Patients on Active Surveillance for Prostate Cancer.
AJR Am J Roentgenol. 2020 Jan 8. 2020;214(4):825-834. doi: 10.2214/AJR.19.22196. Nomogram development. _




Liu Y, Patel SA, Jani AB, Gillespie TW, Patel PR, Godette KD, Hershatter BW, Shelton JW, McDonald MW.
Overall Survival After Treatment of Localized Prostate Cancer With Proton Beam Therapy, External-Beam Photon Therapy, or Brachytherapy.
Clin Genitourin Cancer. 2020 Aug 28. 2020;S1558-7673(20)30199-3. doi: 10.1016/j.clgc.2020.08.009. Retrospective study. _




Oderda M, Diamand R, Albisinni S, Calleris G, Carbone A, Falcone M, Fiard G, Gandaglia G, Marquis A, Marra G, Parola C, Pastore A, Peltier A, Ploussard G, Roumeguère T, Sanchez-Salas R, Simone G, Smelzo S, Witt JH, Gontero P.
Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion.
BJU Int. 2020 Sep 1. doi: 10.1111/bju.15220. Nomogram validation.
_




Patel SA, Switchenko JM, Fischer-Valuck B, Zhang C, Rose BS, Chen RC, Jani AB, Royce TJ.
Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer.
Radiat Oncol. 2020 Sep 15. 2020;15(1):217. doi: 10.1186/s13014-020-01658-5. Retrospective study. _




Scailteux LM, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, Balusson F, Happe A, Nowak E, Oger E.
Overall survival among chemotherapy-naïve castration-resistant prostate cancer patients under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study (the SPEAR cohort).
Am J Epidemiol. 2020 Sep 18. 2020;kwaa190. doi: 10.1093/aje/kwaa190. Retrospective study. _




Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, Fendler WP, Hadaschik B, Kleesiek J, Schäfers M, Weckesser M, Boegemann M, Rahbar K.
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis.
Eur J Nucl Med Mol Imaging. 2020 Sep 24. doi: 10.1007/s00259-020-05040-1. Retrospective study. _



*

Soeterik TFW, van Melick HHE, Dijksman LM, Küsters-Vandevelde H, Stomps S, Schoots IG, Biesma DH, Witjes JA, van Basten JA.
Development and External Validation of a Novel Nomogram to Predict Side-specific Extraprostatic Extension in Patients with Prostate Cancer Undergoing Radical Prostatectomy.
Eur Urol Oncol. 2020 Sep 21. doi: 10.1016/j.euo.2020.08.008. Nomogram development. _




Wen W, Luckenbaugh AN, Bayley CE, Penson DF, Shu XO.
Racial disparities in mortality for patients with prostate cancer after radical prostatectomy.
Cancer. 2020 Sep 8. doi: 10.1002/cncr.33152. Retrospective study. _




Yamamoto Y, Okuda Y, Kanaki T, Tanaka R, Nagahara A, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K.
Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Int J Clin Oncol. 2020 Sep 1. doi: 10.1007/s10147-020-01776-w. Retrospective study. _



*

Yasui M, Sakaguchi M, Jikuya R, Tsutsumi S, Tatenuma T, Noguchi G, Umemoto S, Katayama K, Narimatsu H, Uemura H, Kishida T.
Comparative effectiveness of surgery and radiotherapy for survival of patients with clinically localized prostate cancer: A population-based coarsened exact matching retrospective cohort study.
Oncol Lett. 2020 Aug 24. 2020;20(5):150. doi: 10.3892/ol.2020.12013. Retrospective study. _




Xu N, Ke ZB, Chen YH, Wu YP, Chen SH, Wei Y, Zheng QS, Huang JB, Li XD, Xue XY.
Risk Factors for Pathologically Confirmed Lymph Nodes Metastasis in Patients With Clinical T2N0M0 Stage Prostate Cancer.
Front Oncol. 2020 Aug 14. 2020;10:1547. doi: 10.3389/fonc.2020.01547. Retrospective study. _



*

Zumsteg ZS, Spratt DE, Daskivich TJ, Tighiouart M, Luu M, Rodgers JP, Sandler HM.
Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable: A Secondary Analysis of the RTOG 9408 Randomized Clinical Trial.
JAMA Netw Open. 2020 Sep 9. 2020;3(9):e2015083. doi: 10.1001/jamanetworkopen.2020.15083. Randomized trial. _



Treatment


Abreu AL, Peretsman S, Iwata A, Shakir A, Iwata T, Brooks J, Tafuri A, Ashrafi A, Park D, Cacciamani GE, Kaneko M, Duddalwar V, Aron M, Palmer S, Gill IS.
High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series.
J Urol. 2020 Sep 8. 2020;204(4):741-747. doi: 10.1097/JU.0000000000001126. Retrospective study. _




Alayed Y, Loblaw A, McGuffin M, Chung HT, Tseng CL, D'Alimonte L, Cheung P, Liu S, Chu W, Szumacher E, Helou J, Ravi A, Haider M, Mamedov A, Zhang L, Morton G.
Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost.
Radiother Oncol. 2020 Sep 10. 2020;154:29-35. doi: 10.1016/j.radonc.2020.09.007. Phase 2 trial. _



*

Bartkowiak D, Thamm R, Siegmann A, Böhmer D, Budachb V, Wiegel T.
Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer.
Radiother Oncol. 2020 Sep 11. 2020:S0167-8140(20)30781-7. doi: 10.1016/j.radonc.2020.09.009. Retrospective study; _
Related article of the same author(s)
Bottke D, Bartkowiak D, Siegmann A, Thamm R, Böhmer D, Budach V, Wiegel T. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
Prostate Cancer Prostatic Dis. 2018 Nov 28. 2019;22(2):344-349. doi: 10.1038/s41391-018-0112-3. Retrospective study. _




Byeon S, Kim H, Kim J, Kwon M, Hur JY, Jeon HG, Jeon SS, Lee HM, Park SH.
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study.
Investig Clin Urol. 2020 Sep 8. doi: 10.4111/icu.20200214. Retrospective study. _




Bilgetekin I, Basal FB, Cinkir HY, Esin E, Oksuzoglu B, Demirci U.
Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel.
J Coll Physicians Surg Pak. 2020 Aug;30(8):815-821. doi: 10.29271/jcpsp.2020.08.815. Retrospective study. _




D'Agostino GR, Mancosu P, Di Brina L, Franzese C, Pasini L, Iftode C, Comito T, De Rose F, Guazzoni GF, Scorsetti M.
Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study.
Am J Clin Oncol. 2020 Sep;43(9):628-635. doi: 10.1097/COC.0000000000000721. Phase 2 trial. _




Dinneen E, Haider A, Grierson J, Freeman A, Oxley J, Briggs T, Nathan S, Williams NR, Brew-Graves C, Persad R, Aning J, Jamieson C, Ratynska M, Ben-Salha I, Ball R, Clow R, Allen C, Heffernan-Ho D, Kelly J, Shaw G.
NeuroSAFE frozen section during robot-assisted radical prostatectomy (RARP): Peri-operative and Histopathological Outcomes from the NeuroSAFE PROOF Feasibility Randomised Controlled Trial.
BJU Int. 2020 Sep 27. doi: 10.1111/bju.15256?. Randomized study. _




Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
N Engl J Med. 2020 Sep 10. 2020;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. Phase 3 trial. _




Gartrell BA, Roach M 3rd, Retter A, Sokol GH, Del Priore G, Scher HI.
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer.
Invest New Drugs. 2020 Sep 13. doi: 10.1007/s10637-020-00993-4. Phase 2 trial. _




Ieiri K, Shiota M, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Iwai H, Shiga KI, Yokomizo A, Yoshitake T, Shioyama Y, Ishigami K, Terashima H, Eto M.
The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?
Urol Oncol. 2020 Sep 6. 2020;S1078-1439(20)30384-7. doi: 10.1016/j.urolonc.2020.08.018. Retrospective study. _




Jin K, Qiu S, Zheng X, Li Y, Zhang S, Li J, Liao X, Tu X, Yang L, Wei Q.
Cryotherapy shows no inferiority compared with radical Prostatectomy for low-risk and intermediate-risk localized Prostate Cancer: a real-world study from the SEER database.
J Cancer. 2020 Jul 29. 2020;11(19):5738-5745. doi: 10.7150/jca.38323. Retrospective study. _




Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Fransson AS, Leskinen MJ, Zeke M, Huttunen T, Ginman C; Investigators of the Scandinavian Prostate Cancer Study No. 13.
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer. Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Eur Urol. 2019 Aug 20. 2019;76(6):823-830. doi: 10.1016/j.eururo.2019.08.010. Phase 3 trial. _
Erratum in:
Eur Urol. 2020 Sep 4. doi: 10.1016/j.eururo.2020.08.035. _




Laber DA, Eatrides J, Jaglal MV, Haider M, Visweshwar N, Patel A.
A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer.
Med Oncol. 2020 Sep 26. 2020;37(10):95. doi: 10.1007/s12032-020-01420-7. Phase 1-2 trial. _




Lantz A, Falagario UG, Ratnani P, Jambor I, Dovey Z, Martini A, Lewis S, Lundon D, Nair S, Phillip D, Haines K, Cormio L, Carrieri G, Kryprianou N, Tewari A.
Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings.
Eur Urol Oncol. 2020 Sep 3. 2020;S2588-9311(20)30125-5. doi: 10.1016/j.euo.2020.08.001. Nomogram development. _




Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL.
Cabozantinib plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer.
BJU Int. 2020 Sep 24. doi: 10.1111/bju.15227. Phase 1-2 trial. _




Olsson H, Nordström T, Jäderling F, Egevad L, Vigneswaran HT, Annerstedt M, Grönberg H, Eklund M, Lantz A.
Incorporating MRI and biomarkers in active surveillance protocols - results from the prospective Stockholm3 Active Surveillance trial (STHLM3AS).
J Natl Cancer Inst. 2020 Aug 31. 2020;djaa131. doi: 10.1093/jnci/djaa131. Prospective study. _




Oyman A, Başak M, Özçelik M, Özyükseler DT, Işık S, Yıldırım ME.
Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: A real-world data analysis.
Asia Pac J Clin Oncol. 2020 Sep 5. doi: 10.1111/ajco.13426. Retrospective study. _




Rowe M, Adamson E, McGrane J.
Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy.
Int Cancer Conf J. 2020 Jun 27. 2020;9(4):217-220. doi: 10.1007/s13691-020-00428-0. Case report. _




Takai M, Kato S, Nakano M, Fujimoto S, Iinuma K, Ishida T, Taniguchi M, Tamaki M, Uno M, Takahashi Y, Komeda H, Koie T.
Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration-resistant prostate cancer: A local experience of a multicenter retrospective study.
Asia Pac J Clin Oncol. 2020 Sep 24. doi: 10.1111/ajco.13441. Retrospective study. _




Tripathi A, Supko JG, Gray KP, Melnick Z, Regan MM, Taplin ME, Choudhury AD, Pomerantz MM, Bellmunt J, Yu C, Sun Z, Srinivas S, Kantoff PW, Sweeney CJ, Harshman LC.
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.
Clin Cancer Res. 2020 Sep 17. 2020;clincanres.2306.2020. doi: 10.1158/1078-0432.CCR-20-2306. Phase 1 trial. _



*

Vigna-Taglianti R, Boriano A, Gianello L, Melano A, Bergesio F, Merlotti AM, Reali A, Petrucci R, Russi EG.
Predictive value of Prostate Specific Antigen variations in the last week of salvage radiotherapy for biochemical recurrence of prostate cancer after surgery: A practical approach.
Cancer Rep (Hoboken). 2020 Sep 3. 2020;e1285. doi: 10.1002/cnr2.1285. Retrospective study. _




Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M.
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
J Cancer Res Clin Oncol. 2020 Sep 4. doi: 10.1007/s00432-020-03327-2. Randomized trial. _




Uchida T, Higure T, Kawakami M, Nakano M, Nakajima N, Kim H, Nitta M, Hasegawa M, Kawamura Y, Shoji S, Miyajima A.
What factors affect the operative time of robot-assisted laparoscopic radical prostatectomy?
Surg Endosc. 2020 Sep 9. doi: 10.1007/s00464-020-07946-1. Retrospective study. _



bottom



***********************